Our research focusses on investigating the interactions between host immune physiology and cancer cell intrinsic features that determine response to immunomodulatory treatments. Using bladder cancer patient derived specimens, cell lines, and immunocompetent mouse models to study the tumour-immune interactions, the primary goals of our research program are,
- To advance our understanding on the influence of sex differences and aging in anti-tumour immunity and treatment outcomes.
- To delineate the role of cancer cell intrinsic genetic events in the evolution of variable pre-treatment states of the tumor immune microenvironment.
- To develop combination immune priming approaches to enhance sensitivity to immunomodulatory therapies in cancer.
Dr. Koti is a Veterinarian with PhD in Immunology. She is currently an Associate Professor in the Departments of Biomedical and Molecular Sciences and Obstetrics and Gynaecology at Queen’s University. She is also cross-appointed to the Department of Urology and is a member of the Division of Cancer Biology and Genetics at QCRI.
The Koti Laboratory is located at the Queen’s Cancer Research Institute (QCRI). The QCRI is constituted by Cancer Biology and Genetics, Cancer Care and Epidemiology and Cancer Clinical Trials.
RESEARCH FUNDED BY